Last updated: March 11, 2026
What is NDC 51525-0470?
NDC 51525-0470 corresponds to Gleolan (aminolevulinic acid hydrochloride), indicated for use in fluorescence-guided resection of gliomas. Approved by the FDA in 2017, Gleolan is a specialty pharmaceutical used during neurosurgical procedures.
Market Overview
Therapeutic Context
Gleolan addresses high-grade gliomas, primarily glioblastoma multiforme (GBM). Represents a niche market within neuro-oncology, with an emphasis on surgical adjuncts rather than systemic therapies.
Market Size
- Incidence rates: Approximately 12,000 new cases of glioblastoma annually in the U.S. (SEER, 2022).
- Surgical procedures: About 50-60% of GBM patients undergo resection suitable for fluorescence-guided techniques.
- Market penetration: Limited, given that fluorescence-guided surgery is often adjunct to standard operative procedures.
Competitors
- Standard of care: Surgical resection with or without adjunctive therapies (radiation, chemotherapy).
- Alternatives: 5-ALA (which is chemically similar but marketed abroad), and intraoperative imaging modalities.
Adoption Factors
- Surgeon familiarity with fluorescence-guided techniques.
- Hospital access and approval for FDA-approved agents.
- Cost considerations tied to procedural reimbursement.
Current Sales and Market Penetration
Sales Data
- First-year sales (2017): ~$15 million.
- Recent estimates (2022): ~$35 million.
Usage Trends
- Gradual increase in the number of neurosurgical centers adopting Gleolan.
- Variability with regional hospital preferences and insurance coverage.
Pricing Strategy
- List price (~2022): Approximately $5,400 per dose.
- Cost per procedure: One dose typically suffices per surgery, but use may vary with multiple cycles or repeat procedures.
Price Projection Analysis
Assumptions
- Market growth rate: 8-12% annually, driven by increased adoption.
- Market share: Expected to reach 70% of eligible neurosurgeries by 2027.
- Pricing adjustments: 2-3% annual inflation in list prices; reimbursement rates remain stable.
Projection Table (2023-2027)
| Year |
Estimated Market Size (procedures) |
Estimated Sales Volume |
Average Price |
Projected Revenue |
| 2023 |
7,200 procedures |
7,200 doses |
$5,400 |
$38.9 million |
| 2024 |
8,000 procedures |
8,000 doses |
$5,538 |
$44.3 million |
| 2025 |
8,800 procedures |
8,800 doses |
$5,678 |
$50.0 million |
| 2026 |
9,600 procedures |
9,600 doses |
$5,820 |
$55.8 million |
| 2027 |
10,400 procedures |
10,400 doses |
$5,965 |
$62.0 million |
Note: These figures do not account for competitive threats, regulatory changes, or shifts in clinical practice.
Pricing Risks and Opportunities
- Reimbursement variability: Pending insurance approval, could constrain revenue.
- Market expansion: Potential in countries with growing neurosurgical oncology programs.
- Alternative technologies: Advances in imaging or other intraoperative fluorescence agents could pressure pricing.
Regulatory and Policy Impact
- Continued FDA endorsement sustains market confidence.
- CMS and private insurer coverage policies influence actual revenue realization.
- Potential for off-label use expansion, though currently limited.
Key Takeaways
- NDC 51525-0470 (Gleolan) holds a niche but growing position in neurosurgical oncology.
- Market size estimated at 10,400 procedures annually by 2027, with revenues possibly reaching $62 million.
- Pricing stability remains contingent on reimbursement frameworks and competitive innovations.
- Adoption rates are driven by surgeon familiarity and institutional policies.
- Further expansion depends on clinical evidence, regulatory clarity, and technological advances.
FAQs
1. What are the primary drivers of Gleolan sales growth?
Increasing adoption of fluorescence-guided glioma resection and expansion into international markets.
2. How does the pricing of Gleolan compare to similar agents?
Gleolan’s list price (~$5,400/dose) is comparable to other intraoperative imaging adjuncts but higher than off-label agents like 5-ALA outside the U.S.
3. What are the main barriers to market growth?
Limited awareness among surgeons, insurance reimbursement policies, and the availability of alternative intraoperative visualization methods.
4. How does regulatory status influence market projections?
FDA approval ensures legal use within the U.S., but any regulatory challenges or label updates could impact utilization.
5. Are there international markets with significant potential for Gleolan?
Yes, especially in Europe and Asia, where neurosurgical oncology practices are expanding and regulatory approvals are in place.
Sources:
[1] U.S. Centers for Disease Control and Prevention. (2022). Cancer Statistics.
[2] IQVIA. (2022). Market Data Reports.
[3] FDA. (2017). Gleolan (aminolevulinic acid hydrochloride) Label.
[4] Global Data. (2022). Neurosurgery Device and Drug Market Reports.
